studies

982A AASLD ABSTRACTS HEPATOLOGY, October, 2015
between selected parameters of lipid metabolism and hepatic
steatosis measured using CAP option of transient elastography
(FibroScan), serum HBV-DNA and HBsAg levels during treatment
with tenofovir (TDF), after switching from any antiHBV
nucleos(t)ide analogue (NUC). Methods: The study included
45 HBsAg-positive and HBeAg-negative pts, who within last
3 months have been switched to TDF due to the lack of efficacy
or intolerance to prior treatment. We evaluated the level
of total cholesterol, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides (TG), HBV-DNA and HBsAg
levels. Liver steatosis and fibrosis were assessed FibroScan with
CAP option. In statistical analysis parametric Pearson correlation
and Rang Spearman correlation were used. Results were
considered statistically significant if p